Sensor network performance is governed by the physical placement of sensors and their geometric relationship to the events they measure. To illustrate this, the entirety of this thesis covers the following interconnected subjects: 1) graphical analysis of the variance of the estimation error caused by physical characteristics of an acoustic target source and its geometric location relative to sensor arrays, 2) event/anomaly detection method for time aggregated point sensor data using a parametric Poisson distribution data model, 3) a sensor reduction or placement technique using Bellman optimal estimates of target agent dynamics and probabilistic training data (Goode, Chin, & Roan, 2011), and 4) transforming event monitoring point sensor data into event detection and classification of the direction of travel using a contextual, joint probability, causal relationship, sliding window, and geospatial intelligence (GEOINT) method. / Master of Science

ADHERENCE TO PHARMACOTHERAPY OF OSTEOPOROSIS Author: Martina Santariová Supervisor: PharmDr. Magda Vytřísalová, Ph.D. Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Department of Social and Clinical Pharmacy INTRODUCTION: Adherence is the extent to which the patient's behavior (using of medication, following recommended regimen) is in accordance with the advice of the health care provider. Adherence to pharmacotherapy of osteoporosis, including compliance and persistence, is still suboptimal. OBJECTIVE: The objective of the study was assessing of subjectively evaluated adherence with peroral bisphosphonates used to treat osteoporosis within Czech women. METHODS: A cross-sectional multicentre survey. Data collecting was carried out using anonymous questionnaire in five osteocenters in the Czech Republic. The research was performed between November 2012 and March 2013. Adherence was evaluated using a standardized questionnaire OS- MMAS (Osteoporosis-specific Morisky Medication Adherence Scale). RESULTS: A total of 363 postmenopausal women aged 55 years and older with osteoporosis or osteopenia were participated in the study. 133 (36,6 %) women used weekly dosage forms of BIS (alendronate, alendronate and vitamine D in a fixed combination, risedronate) and 230 (63,4 %) women used...

No description available.